News >

Expert Breaks Down Data With TKI Discontinuation in CML

Angelica Welch
Published: Friday, Nov 09, 2018

Meagan A. Jacoby, MD, PhD

Meagan A. Jacoby, MD, PhD

Most chronic-phase chronic myeloid leukemia (CP-CML) is effectively controlled by TKIs, and data have shown that many patients can safely stop therapy after a few years. However, the challenge is determining who can discontinue treatment.

"Treatment-free remissions (TFRs) are kind of the new treatment goal now. In CP-CML, there have been multiple trials of TKIs that have shown that TFRs are feasible in select patients," said Meagan A. Jacoby, MD, PhD. "But which patients—and how do you pick them?"

In a presentation during the 2018 OncLive® State of the Science Summit™ on Hematologic Malignancies, Jacoby, assistant professor, Department of Medicine Oncology, Division of Bone Marrow Transplantation & Leukemia, Washington University School of Medicine St. Louis, discussed TFRs in patients with CP-CML.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x